Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

2763730-98-7

2763730-98-7 structure

2763730-98-7 structure

Name: SLF1081851 TFA
Chemical Name: SLF1081851 TFA
CAS Number: 2763730-98-7
Molecular Formula: C₂₃H₃₄F₃N₃O₃
Molecular Weight: 457.53
Catalog: Signaling Pathways GPCR/G Protein LPL Receptor
Create Date: 2022-10-12 10:54:35
Modify Date: 2025-08-20 03:32:48
SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system[1][2].

Name	SLF1081851 TFA

Description	SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> LPL Receptor Research Areas >> Inflammation/Immunology
Target	Spns2 (spinster homologue 2)[1]
In Vitro	Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule, and Spns2 exerts the functions to maintain lymph S1P[1]. SLF1081851 (TFA) (compound 16d) (0-5 μM; 18-20 h) inhibits S1P release with an IC50 value of 1.93 μM in Hela cells[1]. SLF1081851 (TFA) (0-30 μM; 20 min) inhibits mSphK1 (recombinant mouse SphK) (10 μM) and mSphK2 (5 μM) in a dose-dependent manner and suggests at least 15-fold selectivity (SphK1 IC50≥30 μM; SphK2 IC50≈30 μM)[1].
In Vivo	SLF1081851 (TFA) (20 mg/kg; i.p., 4 h postdose) significantly inhibits circulating lymphocytes and plasma S1P, and recapitulates the genetic phenotype of Spns2 null mice[1]. Animal Model: C57BL/6 mice[1] Dosage: 20 mg/kg Administration: Intraperitoneal injection; blood was drawn 4 h postdose Result: Significantly decreased circulating lymphocyte count and plasma S1P concentration. Animal Model: SpragueDawley mice (4-week-old)[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose Result: Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0).
References	[1]. Fritzemeier R, et al. Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors. J Med Chem. 2022 Jun 9;65(11):7656-7681. [2]. Lynch Kevin R, et al. Preparation of oxadiazoles as inhibitors of spinster homolog 2 (SPNS2) for use in therapy: World Intellectual Property Organization, WO2022056042[P]. 2022-03-17.

Molecular Formula	C₂₃H₃₄F₃N₃O₃
Molecular Weight	457.53

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.